From January 12th to 15th, Pacific Time, the 44th J.P. Morgan Healthcare Conference was grandly held in San Francisco, USA. As a "bellwether" in the global biopharmaceutical field, this conference brought together top pharmaceutical companies, investment institutions, and industry elites from the world. Beijing Sungen Biomedical Technology Co., Ltd. (hereinafter referred to as "Sungen Biomedical"), a strategically controlled subsidiary of Hotgen Biotech, made a striking appearance at the conference with its next-generation cornerstone drug for tumor immunotherapy, SGT003. Through presentations and demonstrations, the company fully showcased its innovative capabilities and clinical application potentials, attracting significant attention from international capital markets and industry peers.
Tumor treatment has gone through iterations of chemotherapy and targeted therapy, and is now entering an innovative stage focusing on immunotherapy. However, traditional single-target immune checkpoint inhibitors (such as PD-1/PD-L1 monoclonal antibodies) still face problems such as limited response rates and drug resistance. Bispecific antibodies, through their unique mechanism of "simultaneously targeting two targets and acting synergistically," are ushering in the era of "immunotherapy 2.0." Market data showed that the global market size for bispecific antibody drugs for cancer treatment was approximately US$13 billion in 2024, and is expected to exceed US$17 billion in 2025, projected to surge to US$26.8 billion in 2026, maintaining a consistently high compound annual growth rate. However, as of the end of 2024, only 16 bispecific antibody drugs for cancer treatment had been globally approved, and the targeted antigens are relatively limited, far from meeting clinical needs.
As a crucial target in immunotherapy, CTLA4 possesses an irreplaceable core advantage in activating anti-tumor immune responses – it removes inhibition during the initiation phase of immune responses, activates the proliferation and differentiation of naive T cells, and builds a strong immune foundation for subsequent tumor killing. It is one of the key targets for achieving long-term anti-tumor efficacy. Sungen Biomedical deeply cultivates into research of tumor immune mechanisms, accurately grasping industry pain points and the core value of the CTLA4 target. They have innovatively built a dual-target drug development platform focusing on CTLA4 and have established a series of bispecific antibody product pipelines. SGT003 is one of these promising potential First-in-Class candidate drugs.
The core innovation of SGT003 lies in its dual mechanisms of action: "precisely eliminating tumor microenvironment Tregs + activating anti-tumor immunity." In preclinical studies, it demonstrated excellent tumor-specific killing effects, not only precisely targeting on tumor tissue but also regulating the tumor microenvironment and trigering the body's own immune responses. This significantly reduces the immune activation - related toxic effects of currently marketed CTLA4 antibodies and effectively covers a broad range of solid tumor patients resistant or unresponsive to traditional treatments. Compared to similar drugs, SGT003 shows significant advantages in target affinity, tissue penetration and safety, providing a new treatment option for cancer patients. Currently, SGT003 has completed preclinical development and been planned for dual IND filing in the US and China in 2026.
As a cornerstone therapy of the new generation, SGT003's unique design and global development vision fully demonstrate the breakthroughs of Chinese pharmaceuticals in the field of original innovation, laying a solid foundation for global R&D and commercialization of SGT003. In the future, Sungen Biomedical will continue to advance the clinical translation and global deployment of SGT003, breaking down industry barriers through original innovation and helping Chinese innovative drugs gain a core position in the global oncology immunotherapy market.
Updated: Jan 14, 2026
